S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)

PDS Biotechnology Stock Price, News & Analysis (NASDAQ:PDSB)

$5.24
-0.04 (-0.76%)
(As of 02:46 PM ET)
Compare
Today's Range
$5.19
▼
$5.36
50-Day Range
$3.95
▼
$6.58
52-Week Range
$3.80
▼
$13.65
Volume
227,140 shs
Average Volume
607,950 shs
Market Capitalization
$163.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

PDS Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
237.2% Upside
$17.67 Price Target
Short Interest
Bearish
16.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.43) to ($1.54) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

872nd out of 949 stocks

Pharmaceutical Preparations Industry

401st out of 427 stocks

See Top Rated MarketRank™ Stocks Here

PDSB stock logo

About PDS Biotechnology Stock (NASDAQ:PDSB)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDSB Stock Price History

PDSB Stock News Headlines

November 28, 2023 | marketwatch.com
PDS Biotechnology CFO Matthew Hill to Exit; Lars Boesgaard Named as Replacement
November 28, 2023 | markets.businessinsider.com
PDS Biotechnology Appoints Lars Boesgaard To Succeed Matthew Hill As CFO
December 5, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
November 28, 2023 | finance.yahoo.com
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
November 17, 2023 | markets.businessinsider.com
Positive Outlook for PDS Biotechnology: Strong Q3 Financials, Promising Development Pipeline, and Strategic Advancements
November 15, 2023 | finance.yahoo.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript
November 14, 2023 | marketwatch.com
PDS Biotechnology Shares Rise 20% After Narrower-Than-Expected 3Q Loss
November 14, 2023 | finanznachrichten.de
PDS Biotechnology Corporation: PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
December 5, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
November 14, 2023 | finance.yahoo.com
PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ...
November 14, 2023 | benzinga.com
PDS Biotechnology: Q3 Earnings Insights
November 14, 2023 | finance.yahoo.com
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 | benzinga.com
A Preview Of PDS Biotechnology's Earnings
November 10, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Shattuck Labs (STTK)
November 9, 2023 | msn.com
PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy
November 9, 2023 | finance.yahoo.com
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
November 7, 2023 | finance.yahoo.com
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
October 28, 2023 | seekingalpha.com
PDSB PDS Biotechnology Corporation
October 24, 2023 | markets.businessinsider.com
Promising Potential of PDS Biotechnology’s PDS0101 in HPV16-Positive HNSCC Treatment: An Analysis of the VERSATILE-002 Phase 2 Study Results
October 23, 2023 | finance.yahoo.com
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
October 11, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for PDS Biotechnology
October 11, 2023 | finance.yahoo.com
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
October 6, 2023 | markets.businessinsider.com
Promising Clinical Trial Results and Undervalued Potential Bolster Buy Rating for PDS Biotechnology: An Analysis
October 3, 2023 | finance.yahoo.com
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)
October 2, 2023 | finance.yahoo.com
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
September 26, 2023 | finance.yahoo.com
PDS Biotech to Present at the LD Micro Main Event XVI
September 25, 2023 | finance.yahoo.com
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
See More Headlines
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/26/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PDSB
CUSIP
N/A
CIK
1472091
Web
www.pdsbiotech.com
Phone
(800) 208-3343
Fax
908-790-1212
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.67
High Stock Price Target
$21.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+237.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-40,850,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-144.24%
Return on Assets
-76.85%

Debt

Debt-to-Equity Ratio
0.96
Current Ratio
6.21
Quick Ratio
6.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.55 per share
Price / Book
3.38

Miscellaneous

Outstanding Shares
31,110,000
Free Float
27,997,000
Market Cap
$163.02 million
Optionable
Not Optionable
Beta
2.01
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Frank K. Bedu-Addo Ph.D. (Age 58)
    President, CEO & Director
    Comp: $854.1k
  • Mr. Matthew C. Hill CPAMr. Matthew C. Hill CPA (Age 54)
    CFO, Principal Financial & Accounting Officer
    Comp: $504.09k
  • Ms. Lauren V. Wood M.D. (Age 63)
    Chief Medical Officer
    Comp: $568.5k
  • Dr. Joe J. Dervan
    VP of Research & Development
  • Dr. Gregory L. Conn Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $220.46k
  • Ms. Deanne Randolph
    VP of Commercial Development & Head of Investor Relations
  • Mr. Spencer Brown J.D. (Age 53)
    Senior VP & General Counsel
  • Ms. Nathalie Riebel
    Senior Vice President of Clinical Operations
  • Mr. Sanjay Zaveri
    Senior Vice President of Business Development
  • Ms. Janetta Trochimiuk (Age 60)
    Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions














PDSB Stock Analysis - Frequently Asked Questions

Should I buy or sell PDS Biotechnology stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PDSB shares.
View PDSB analyst ratings or view top-rated stocks.

What is PDS Biotechnology's stock price target for 2024?

3 equities research analysts have issued 12-month price targets for PDS Biotechnology's shares. Their PDSB share price targets range from $12.00 to $21.00. On average, they anticipate the company's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 237.2% from the stock's current price.
View analysts price targets for PDSB or view top-rated stocks among Wall Street analysts.

How have PDSB shares performed in 2023?

PDS Biotechnology's stock was trading at $13.20 at the beginning of 2023. Since then, PDSB shares have decreased by 60.3% and is now trading at $5.24.
View the best growth stocks for 2023 here.

When is PDS Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our PDSB earnings forecast.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. During the same quarter last year, the firm posted ($0.23) earnings per share.

What other stocks do shareholders of PDS Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Boxlight (BOXL), Otonomy (OTIC), Bionano Genomics (BNGO), CymaBay Therapeutics (CBAY), Cerecor (CERC), Enterprise Products Partners (EPD) and Evofem Biosciences (EVFM).

Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.80%), LPL Financial LLC (0.76%), Commonwealth Equity Services LLC (0.22%), Vontobel Holding Ltd. (0.13%), Simplex Trading LLC (0.00%) and Trexquant Investment LP (0.08%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill, Steve C Glover and Voorhees Seth Van.
View institutional ownership trends.

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PDSB) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -